Table 3.
Response in patients receiving G-B in cohort 1 of the GREEN study at final response assessment (intent-to-treat population)
| Response, n (%) | All patients (N = 158) | Fit patientsa (n = 70) | Unfit patientsb (n = 88) |
|---|---|---|---|
| Overall response | 128 (81.0) | 60 (85.7) | 68 (77.3) |
| Complete responsec | 55 (34.8) | 23 (32.9) | 32 (36.4) |
| Partial response | 73 (46.2) | 37 (52.9) | 36 (40.9) |
| Stable disease | 13 (8.2) | 4 (5.7) | 9 (10.2) |
| Progressive disease | 2 (1.3) | 1 (1.4) | 1 (1.1) |
| Failure (due to missing assessment) | 15 (9.5) | 5 (7.1) | 10 (11.4) |
CIRS Cumulative Illness Rating Scale, CrCl creatinine clearance, G-B obinutuzumab plus bendamustine
a CIRS ≤6 and CrCl ≥70 ml/min
b CIRS >6 and/or CrCl <70 ml/min
c Including complete response with incomplete marrow recovery